140 related articles for article (PubMed ID: 27471639)
1. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
Kroesen M; Büll C; Gielen PR; Brok IC; Armandari I; Wassink M; Looman MW; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2016 Jun; 5(6):e1164919. PubMed ID: 27471639
[TBL] [Abstract][Full Text] [Related]
2. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy.
Zebertavage L; Schopf A; Nielsen M; Matthews J; Erbe AK; Aiken TJ; Katz S; Sun C; Witt CM; Rakhmilevich AL; Sondel PM
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731089
[No Abstract] [Full Text] [Related]
4. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Mora J; Climent A; Roldán M; Flores MC; Varo A; Perez-Jaume S; Jou C; Celma MS; Lazaro JJ; Cheung I; Castañeda A; Gorostegui M; Rodriguez E; Chamorro S; Muñoz JP; Cheung NK
Front Oncol; 2024; 14():1380917. PubMed ID: 38812778
[TBL] [Abstract][Full Text] [Related]
5. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
Perez Horta Z; Goldberg JL; Sondel PM
Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
[TBL] [Abstract][Full Text] [Related]
6. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Di Blasio S; Wortel IM; van Bladel DA; de Vries LE; Duiveman-de Boer T; Worah K; de Haas N; Buschow SI; de Vries IJ; Figdor CG; Hato SV
Oncoimmunology; 2016 Aug; 5(8):e1192739. PubMed ID: 27622063
[TBL] [Abstract][Full Text] [Related]
7. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
9. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model.
van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.
Fang E; Wang J; Hong M; Zheng L; Tong Q
Biochem Biophys Res Commun; 2019 Jan; 508(1):9-16. PubMed ID: 30466785
[TBL] [Abstract][Full Text] [Related]
12. GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J; Shevchenko J; Sennikov S
Front Immunol; 2024; 15():1371345. PubMed ID: 38558810
[TBL] [Abstract][Full Text] [Related]
13. Targeting the myeloid microenvironment in neuroblastoma.
Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
[TBL] [Abstract][Full Text] [Related]
14. A promising anoikis-related prognostic signature predicts prognosis of skin cutaneous melanoma.
Yue Z; Wang D; Li X
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17757-17770. PubMed ID: 37930439
[TBL] [Abstract][Full Text] [Related]
15. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction.
Cupit-Link M; Federico SM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760578
[TBL] [Abstract][Full Text] [Related]
16. Biology of GD2 ganglioside: implications for cancer immunotherapy.
Machy P; Mortier E; Birklé S
Front Pharmacol; 2023; 14():1249929. PubMed ID: 37670947
[TBL] [Abstract][Full Text] [Related]
17. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.
Ren R; Xiong C; Ma R; Wang Y; Yue T; Yu J; Shao B
MedComm (2020); 2023 Aug; 4(4):e323. PubMed ID: 37547175
[TBL] [Abstract][Full Text] [Related]
18. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
Vitale C; Bottino C; Castriconi R
Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer.
Lian B; Chen X; Shen K
Front Immunol; 2023; 14():1164514. PubMed ID: 36969235
[TBL] [Abstract][Full Text] [Related]
20. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
